The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ASCO 2020 | DS-8201 + pembro in patients HER2+ breast and NSCLC

Name: DS-8201 + pembro in patients HER2+ breast and NSCLC
Uploaded: 2020-06-11T00:00:00Z
Duration: 2 min 24 s
Description: Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses data from a phase II study which evaluated the use of trastuzumab deruxtecan in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Sanjay Popat • 11 Jun 2020

ASCO 2020

Breast Cancer Lung Cancer Non-Small Cell Lung Cancer Trastuzumab deruxtecan

Sanjay Popat, BSc, MBBS, FRCP, PhD, The Royal Marsden NHS Foundation Trust, London, UK, discusses data from a phase II study which evaluated the use of trastuzumab deruxtecan in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).